Results 241 to 250 of about 733,596 (345)
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
Publication: 'Guide to Creative Commons for humanities and social science monograph authors'
Martin Paul Eve
openalex +1 more source
Editorial: Autobiographical memory, narrative skills, self processes, and individual differences: experimental, clinical, and forensic implications. [PDF]
Maiorano T, Simione L, Lee S, Vagni M.
europepmc +1 more source
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho+11 more
wiley +1 more source
Correction: The effect of basic public health service equalization on settlement intention of migrant workers in China: the mediating effect model based on subjective feelings. [PDF]
Liu P, Long Z, Ding X.
europepmc +1 more source
Comprehensive cancer centre (CCCs) and CCCs of Excellence (CCCoE) integration in healthcare. Through outreach to surrounding community hospitals, CCCs enable wider access to top‐clinical cancer treatments and care, thereby facilitating the swift enrolment of patients into data‐rich clinical trials (PI‐initiated trials testing new concepts, drug ...
Anton Berns+4 more
wiley +1 more source
Correction: Perceived cognitive loss, symptomology, and psychological well-being with bipolar disorder. [PDF]
Haglili O+4 more
europepmc +1 more source
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald+18 more
wiley +1 more source